Your session is about to expire
← Back to Search
Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing the combination of pembrolizumab with different chemotherapies and/or other immunotherapy drugs to see if it is more effective and has fewer side effects than other treatments for people with squamous or non-squamous NSCLC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am allergic to carboplatin, paclitaxel, pemetrexed, or their ingredients.I have a GI condition or liver issues that could affect medication absorption.I have been diagnosed with small cell lung cancer.I have not received any live vaccines other than approved COVID-19 vaccines in the last 30 days.I am currently being treated for an infection.I had major surgery less than 3 weeks ago.I agree to use birth control and not donate sperm during and up to 6 months after treatment.I stopped immunotherapy due to a severe side effect.I can provide a recent or archived tumor sample not previously treated with radiation.I have a history of Hepatitis B or an active Hepatitis C infection.I am on chemotherapy and have serious digestive system issues.I've had lung radiation over 30 Gray in the last 6 months.I have fluid buildup in my abdomen or around my lungs and am taking Alimta.My organs are functioning well enough for treatment.I haven't had cancer treatment in the last 4 weeks or have recovered from its side effects.I am taking medication that affects liver enzymes and can't stop during the study.I am not pregnant or breastfeeding, and if I can have children, I agree to use contraception as required.I cannot or will not take folic acid or vitamin B12 supplements.My nonsquamous NSCLC is not eligible for approved targeted treatments.My lung cancer is confirmed to be stage IV.I have cancer that has spread to my brain or spinal cord.You had a bad allergic reaction to a type of medicine called monoclonal antibodies in the past.I cannot stop taking aspirin or NSAIDs for 5 days, or 8 days for long-acting ones.I am taking medication that affects liver enzymes and cannot stop during the study.I have received an organ or tissue transplant from another person.I have serious heart problems, including recent heart attacks or severe heart failure.I have been treated for an autoimmune disease in the last 2 years.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have moderate nerve pain or tingling.I have another cancer that is getting worse or was treated in the last 2 years.I will not need any cancer treatment other than the study's while participating.I haven't had systemic treatment for my metastatic NSCLC.I have been treated with immunotherapy targeting PD-1, PD-L1, or PD-L2.I have a known history of HIV.I have received chemotherapy or targeted therapy for my cancer after it spread.I have had or currently have lung inflammation treated with steroids.
- Group 1: Pembrolizumab+MK-0482+Carboplatin+Paclitaxel
- Group 2: Pembrolizumab+Vibostolimab+Carboplatin + Paclitaxel
- Group 3: Pembrolizumab+Vibostolimab+Carboplatin + Pemetrexed
- Group 4: Pembrolizumab+Boserolimab+Carboplatin+Paclitaxel
- Group 5: Pembrolizumab+Boserolimab+Carboplatin+Pemetrexed
- Group 6: Pembrolizumab+MK-4830+Carboplatin+Pemetrexed
- Group 7: Pembrolizumab+MK-0482+Carboplatin+Pemetrexed
- Group 8: Pembrolizumab+MK-4830+Carboplatin+Paclitaxel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many sites is this study being conducted?
"Currently, this study is enrolling patients from the University of California San Francisco ( Site 0007) in San Francisco, California, Banner MD Anderson Cancer Center ( Site 0001) in Gilbert, Arizona and City of Hope ( Site 0014). Additionally, there are 18 other locations that are participating."
Is this study still recruiting patients for participation?
"From what is published on clinicaltrials.gov, it seems as if this study is still recruiting patients. The trial was initially posted on December 19th, 2019 with the most recent update occurring on October 31st, 2020."
Has Pembrolizumab been cleared by the FDA?
"Pembrolizumab falls into Phase 2 of clinical trials, so there is some data indicating that it is safe but no efficacy data yet. Our team at Power rates its safety as a 2."
What other investigations have been conducted with Pembrolizumab?
"The first clinical trial for pembrolizumab was at City of Hope Comprehensive Cancer Center in 1997. As of now, there have been a total of 1965 completed trials with 2127 more active ones. A large portion of these active trials are taking place in San Francisco, California."
What are the usual indications for Pembrolizumab?
"Pembrolizumab is a medication that can be used to fight cancerous growths, unresectable melanoma, and microsatellite instability high."
How many people does this research project allow to enroll?
"Yes, you are correct. The trial is looking for 360 participants and is being conducted at 18 different locations. According to the clinicaltrials.gov website, the last update was on 10/31/2022 and it was first posted on 12/19/2019."
Share this study with friends
Copy Link
Messenger